225 related articles for article (PubMed ID: 17945482)
41. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Vázquez S; León L; Fernández O; Lázaro M; Grande E; Aparicio L
Adv Ther; 2012 Mar; 29(3):202-17. PubMed ID: 22328304
[TBL] [Abstract][Full Text] [Related]
42. Sunitinib maleate.
Atkins M; Jones CA; Kirkpatrick P
Nat Rev Drug Discov; 2006 Apr; 5(4):279-80. PubMed ID: 16628834
[No Abstract] [Full Text] [Related]
43. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
van der Veldt AA; van den Eertwegh AJ; Boven E
Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
[TBL] [Abstract][Full Text] [Related]
44. [Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma].
Vollmer H
Med Monatsschr Pharm; 2006 Oct; 29(10):386-7. PubMed ID: 17058904
[No Abstract] [Full Text] [Related]
45. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
46. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
47. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
Hutson TE
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
[TBL] [Abstract][Full Text] [Related]
48. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Faivre S; Delbaldo C; Vera K; Robert C; Lozahic S; Lassau N; Bello C; Deprimo S; Brega N; Massimini G; Armand JP; Scigalla P; Raymond E
J Clin Oncol; 2006 Jan; 24(1):25-35. PubMed ID: 16314617
[TBL] [Abstract][Full Text] [Related]
49. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
50. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
George DJ
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):753s-757s. PubMed ID: 17255305
[TBL] [Abstract][Full Text] [Related]
51. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
52. Molecular basis for sunitinib efficacy and future clinical development.
Faivre S; Demetri G; Sargent W; Raymond E
Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
[TBL] [Abstract][Full Text] [Related]
53. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
Mansueto G; Longo F
Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
[No Abstract] [Full Text] [Related]
54. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.
Baccala A; Hedgepeth R; Kaouk J; Magi-Galluzzi C; Gilligan T; Fergany A
Int J Urol; 2007 Dec; 14(12):1095-7; discussion 1097. PubMed ID: 18036049
[TBL] [Abstract][Full Text] [Related]
55. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
56. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
Schöffski P; Bukowski R; Flodgren P; Ravaud A
Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
[TBL] [Abstract][Full Text] [Related]
57. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Mackay HJ; Tinker A; Winquist E; Thomas G; Swenerton K; Oza A; Sederias J; Ivy P; Eisenhauer EA
Gynecol Oncol; 2010 Feb; 116(2):163-7. PubMed ID: 19740535
[TBL] [Abstract][Full Text] [Related]
58. New challenges in kidney cancer therapy: sunitinib.
Izzedine H; Billemont B; Thibault F; Rixe O
Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
[No Abstract] [Full Text] [Related]
59. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
60. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
